Evaluation of the Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes in China

Meng-Ting Cai†, Song Qiao†, Qi-Lun Lai‡, Yang Zheng§, Fan Yang¶, Gao-Li Fang‖, Chun-Hong Shen¶, Yin-Xi Zhang†* and Mei-Ping Ding†*

† Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, ‡ Department of Neurology, Zhejiang Hospital, Hangzhou, China, § Department of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China, ¶ Department of Neurology, People’s Hospital of Anyang City, Anyang, China, ‖ Department of Neurology, Zhejiang Chinese Medicine and Western Medicine Integrated Hospital, Hangzhou, China

Background: Recently, the paraneoplastic neurologic syndrome (PNS) diagnostic criteria have received a major update with a new score system over the past 16 years. We aimed to evaluate the diagnostic performance and clinical utility in China.

Methods: An eligible cohort of 113 Chinese patients diagnosed with PNSs from the Second Affiliated Hospital School of Medicine Zhejiang University and published data were enrolled retrospectively. Data including clinical phenotype, antibody type, the presence of cancer, and duration of follow-up were reviewed and re-evaluated to classify the diagnostic levels for the 2004 and 2021 PNS criteria. The performances of these 2 criteria were compared. The critical parameters of antibody and cancer for the updated criteria were further explored.

Results: The cohort consisted of 69 males and 44 females with a median age of 60 years. Limbic encephalitis (23, 20.4%), anti-Hu antibody (32, 28.3%), and small-cell lung cancer (32, 28.3%) were the most common clinical phenotype, detected antibody, and concomitant cancer, respectively. A total of 97 (85.8%) patients were diagnosed with definite PNS according to the 2004 criteria: only 42.3% (41/97) fulfilled the 2021 criteria, while the remaining 40, 14, and 2 re-diagnosed with probable PNS, possible PNS, and non-PNS. The requirement of cancers consistent with antibody and phenotype increased the specificity and thus greatly enhanced the accuracy of the 2021 criteria.

Conclusion: The updated criteria for PNS emphasized the consistency between cancer phenotype and antibody and showed a better diagnostic value. A better diagnostic yield could benefit disease management.

Keywords: paraneoplastic neurologic syndrome, updated diagnostic criteria, clinical phenotype, antibody, cancer
INTRODUCTION

Paraneoplastic neurologic syndromes (PNSs) are a group of neurological disorders in association with cancer and have an immune-mediated pathogenesis that is supported by the frequent presence of specific neuronal antibodies (1, 2). Their diverse and complicated presentations with involvement of the nervous system had various mimics, including infections, autoimmune non-paraneoplastic diseases, tumors, neurodegenerative disorders, and toxic/metabolic disturbances (3, 4). Even though the detection of specific antibodies and cancers provided great favor for identification, a certain proportion of patients might still be difficult to diagnose. Recent population-based studies suggested an increasing incidence of PNS over time with a range of 2–10 per million person-years, and it developed in 1 in every 334 patients with cancers (5–8). Apart from the increased awareness and improved detection techniques, updated criteria were needed to increase the diagnostic rate, especially for those with new antibodies.

Recently, the PNS-Care panel updated the diagnostic criteria for PNS on the basis of the new phenotypes and antibodies since the proposal of the first criteria in 2004 (9, 10). A new clinical scoring system (PNS-Care Score) was developed to increase diagnostic accuracy in complicated clinical scenarios. The diagnostic certainty was divided into 3 levels (possible, probable, and definite PNS) according to the coherence between clinical phenotype, antibody, and cancer. And 3 new risk categories (high-risk, intermediate-risk, and low-risk phenotypes) were created to stratify antibodies and their associated syndromes with more precise terminologies (11). As suggested, the new criteria provided a broad, comprehensive approach for unambiguous diagnostic certainty, yet patients with negative neuronal antibodies might be underestimated (10, 11). However, no study has evaluated the application of the new criteria to date. We therefore aimed to evaluate the validity of the updated diagnostic criteria for PNSs in a cohort of Chinese patients and to compare the diagnostic performance with the 2004 PNS criteria.

METHODS

Study Design

We retrospectively collected 189 cases with a diagnosis of possible or definite PNS by the 2004 criteria (9) from 2 origins. Forty-three patients with a follow-up over 2 years were enrolled from the Second Affiliated Hospital School of Medicine Zhejiang University between January 2016 and June 2019. Others were from PubMed, Web of Science, and Embase by 2 independent investigators from January 2004 to April 2021 (12–45). Relative terms (including variations) of “paraneoplastic neurologic syndrome”, “paraneoplastic neurological syndrome”, and “paraneoplastic syndrome, nervous system” were used for search with restriction of affiliation in China. We retrieved all relevant articles and searched their reference tables to identify as many additional studies as possible. Only full articles in English and Chinese were included in the review; publications in abstract form were not considered. Detailed clinical data were collected, including the clinical phenotypes, antibodies (with detection methods), associated tumors, follow-up duration, demographic characteristics, other clinical or paraclinical results, and prognosis. Among them, cases with missing data were removed. Furthermore, patients with the following diagnoses were also excluded according to the updated criteria (10): inflammatory myopathies (such as dermatomyositis, polymyositis, and necrotizing myopathies), myasthenia gravis, polyneuropathies associated with monoclonal gammopathies, and paraneoplastic retinopathy, optic neuritis, and cochlear vestibulopathy. The flowchart is presented in Figure 1. Our study was approved by the ethics committee of the Second Affiliated Hospital School of Medicine Zhejiang University.

Evaluation of the 2 Criteria

The 2004 criteria classified the diagnosis as definite and possible levels mainly according to the presence of well-characterized antibodies and/or cancers (Supplementary Table 1) (9). And the 2021 criteria were divided into 3 diagnostic certainties with 3 parameters of clinical level, laboratory level, and cancer. The range scores corresponded to definite (≥8), probable (6–7), and possible (4–5) diagnoses of PNSs, respectively, as a score ≤3 was considered as non-PNS (Supplementary Table 2) (10). The initial data of all patients were reviewed and re-evaluated using the 2004 and 2021 criteria based on the current time by 2 neurologists independently. A final consensus was achieved after discussion in any discrepant cases. We calculated the diagnostic values of the 2 criteria and compared their performance in the setting of different tumor and antibody conditions.

Statistical Analyses

All analyses were performed with R software. The results were presented as median [interquartile range (IQR)] or number (%). Chi-square test and Mann–Whitney U test were used to calculate the difference between different groups. The statistical significance was adopted at p < 0.05. We calculated the number of true positives (TP; presence of antibody/cancer in patients with definite PNS), true negatives (TN; absence of antibody/cancer in patients without definite PNS), false positives (FP; presence of antibody/cancer in patients without definite PNS), and false negatives (FN; absence of antibody/cancer in patients with definite PNS). Significant differences were determined with 95% confidence intervals. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated.

RESULTS

Clinical Manifestations

A total of 113 patients from 24 centers in 11 provinces across China were eventually included in the study, with the largest proportion of our cohort in Zhejiang Province (43, 38.1%). They
were between the ages of 29 and 83 (median 60.0, IQR = 53.0–65.0) and were mainly males (61.1%). Among the clinical phenotypes, limbic encephalitis (LE) was the most frequent (23, 20.4%), followed by subacute cerebellar degeneration (SCD)/rapidly progressive cerebellar syndrome (RPCS) (18, 15.9%) and Lambert–Eaton myasthenic syndrome (LEMS) (14, 12.4%) (Figure 2A). Referring to the positively associated antibodies, the anti-Hu antibody was the most frequent (32/90, 35.6%), followed by anti-gamma-aminobutyric acid-b receptor (GABABR) antibody (22/90, 24.4%) and anti-CV2 antibody (13/90, 14.4%) (Figure 2B). There were 14 patients with at least 2 coexisting antibodies. Interestingly, 12 of them were positive for anti-Hu antibodies, with a frequent combination of anti-GABABR antibodies (8/12, 66.7%) and even triple antibodies with anti-N-methyl-D-aspartate receptor (NMDAR) antibodies (2/12, 16.7%). Coexistence of anti-Yo and anti-CV2 antibodies was found in 2 patients, as other combinations of anti-Hu plus anti-Yo/ SOX1/Ri antibodies and anti-Yo plus anti-voltage-gated calcium channel (anti-VGCC) antibodies were each found in 1 patient. More than 20 types of tumors were found in 81 patients, most of which were lung cancers, including small-cell lung cancer (SCLC) (32/81, 39.5%) and non-SCLC (NSCLC) (18/81, 22.2%) (Figure 2C). Among them, there were 42 patients receiving oncotherapies. Among 81 patients with cancers, 27 died, 6 worsened, and 28 obtained remission, as compared with those without cancers of 7, 4, and 19, respectively. Table 1 exhibits the details.

The characteristics of patients with specific antibodies are shown in Supplementary Table 3. The patients with anti-SOX1 antibody were the oldest (median = 69.0 years, IQR = 65.0–72.0), with the highest proportion of males (100%). LE was the most frequent syndrome in various antibodies including anti-amphiphysin, anti-GABA<sub>β</sub>R, anti-NMDAR, and anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) antibodies, corresponding to SCD/RPCS in anti-Yo and anti-CV2 antibodies, LEMS in anti-SOX1 and anti-VGCC antibodies, and peripheral neuropathy in anti-CV2 and anti-Ma2 antibodies. The concomitant cancers varied among each antibody, yet patients with high-risk antibodies of anti-Yo, anti-Ma2, and anti-Ri antibodies showed lower involvement rate of 53.8%, 55.6%, and 50.0%, respectively. NSCLC was found to be the most frequent among anti-Hu (12/32, 37.5%) and anti-GABA<sub>β</sub>R (6/22, 27.3%) antibodies, while SCLC was the most common among anti-CV2 (3/10, 30.0%) and anti-amphiphysin antibodies (2/5, 40%). Regarding the outcomes, patients with anti-Hu and anti-SOX1 antibodies showed higher mortality (40.6%, 66.7%), while more patients with anti-Yo and anti-CV2 obtained remission (61.5%, 50.0%).

According to the updated criteria, SCLC, NSCLC, breast carcinoma, ovarian carcinoma, and lymphomas were highly relevant with PNSs irrespective of the antibody status. As shown in Supplementary Table 4, patients with SCLC presented more frequently with LE and LEMS (both 8/32, 25.0%) and combined mostly with anti-Hu antibody (5/32, 27.8%). The patients with NSCLC had more encephalitis (5/18, 27.8%) and anti-Hu antibody (12/18, 66.7%). By contrast, only a few patients were found to have breast carcinoma (n = 7), ovarian carcinoma (n = 2), and lymphomas (n = 1). However, the small number of patients in each cancer category prevented us from reaching a definite conclusion.
FIGURE 2 | The distributions of clinical phenotypes (A), antibody types (B), and cancers (C). The total number of clinical phenotypes and cancers was 113, compared with 128 antibodies. The former 2 features were unique in each patient, while coexisting antibodies were found in 14 patients (13 with 2 antibodies, and 1 with 3 antibodies). *Only 23 of the 35 patients initially diagnosed with LE fulfilled the 2016 Lancet criteria (46), and the rest were classified as encephalitis.

Eleven types of cancers for each patient, including testicular cancer, cervical carcinoma, spinal cord tumor, palatal squamous epithelial carcinoma, lymphoepithelial carcinoma, mucosa-associated lymphoid tissue lymphoma, multiple myeloma, non-Hodgkin lymphoma, bladder cancer, ganglieneuroma, and gastric carcinoma. AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; AQP4, aquaporin 4; CGPO, chronic gastrointestinal pseudo-obstruction; EM, encephalomyelitis; GABA\(_{\text{A}}\)R, gamma-aminobutyric acid-B receptor; LE, limbic encephalitis; LEMS, Lambert–Eaton myasthenic syndrome; NMDAR, N-methyl-D-aspartate receptor; NSCLC, non-small-cell lung cancer; RPCS, rapidly progressive cerebellar syndrome; SCLC, small-cell lung cancer; SNN, sensory neuronopathy; VGCC, voltage-gated calcium channel.
TABLE 1 | Summary of patients with PNSs.

| Neurologic phenotype | Antibody | Cancer | Diagnostic level |
|----------------------|----------|--------|------------------|
| 2004 criteria        |          |        |                  |
| Classical (n = 80)   | Well characterized (n = 67) | Present (n = 90) | Definite (n = 97) |
| Non-classical (n = 33) | Partially characterized (n = 0) | Absent (n = 23) | Possible (n = 16) |
|                      | Others or negative (n = 46) | Found, consistent with phenotype and (if present) antibody, or not consistent but antigen expression demonstrated (n = 69) | Definite (n = 42) |
| 2021 criteria        |          |        |                  |
| High-risk (n = 68)   | High-risk (n = 69) | Not found (or not consistent) but follow-up < 2 years (n = 26) | Probable (n = 49) |
| Intermediate-risk (n = 45) | Intermediate-risk (n = 20) | Not found but follow-up ≥ 2 years (n = 27) | Possible (n = 19) |
| Defined epidemiologically not associated with cancer (n = 0) | Low-risk or negative (n = 24) | | Non-PNS (n = 3) |

IQR, interquartile range; IVIG, intravenous immunoglobulin; PNS, paraneoplastic neurologic syndrome.

*Any combination of surgery, chemotherapy, and radiotherapy.

**TABLE 2 | Definition and classification of the 2 criteria.

**Evaluation of Patients With the 2 Criteria**

The PNS criteria are mainly based on 3 aspects consisting of a neurologic syndrome, antibody, and cancer, even though the definitions of each factor were somewhere modified and updated. As shown in Table 2, each classification and the number of corresponding patients were rather different. In detail, the classical syndromes in the 2004 criteria were divided into high-risk (68/80, 85.0%) and intermediate-risk (12/80, 15.0%) phenotypes in the 2021 criteria, as the latter 12 patients with a diagnosis of LE failed to fulfill the 2016 Lancet criteria by Graus et al. (46). The high-risk antibodies consisted of the well-characterized antibodies by the 2004 criteria (67, 59.3%) and the new anti-SOX1 antibody (2, 1.8%). Yet no partially characterized antibody was found. The intermediate-risk antibody group included 20 patients with anti-GABABR, anti-AMPAR, anti-NMDAR, and anti-VGCC antibodies. The low-risk antibody [anti-aquaporin 4 (anti-AQP4) antibody] was only found in 1 patient. Importantly, the updated PNS criteria had more specific and stricter classifications for clinical, laboratory, and cancer parameters. Reflected by PNS-Care Score system (Figure 3A), the median scores of the parameters in this cohort were 3.0 (IQR = 2.0–3.0), 3.0 (IQR = 2.0–3.0), 4.0 (IQR = 1.0–4.0), with a total score of 7.0 (IQR = 6.0–9.0). Accordingly, the number of patients with definite, probable, and possible PNS was 42, 49, and 19, respectively. By contrast, a majority acquired a definite diagnosis from the 2004 criteria (97, 85.8%). Among them, only 42.3% (41/97) patients had a definite diagnosis, as the remaining 40, 14, and 2 were re-diagnosed with probable PNS, possible PNS, and non-PNS according to the 2021 criteria (Figure 3B). On the contrary, a patient with GABABR encephalitis and SCLC previously diagnosed with possible PNS fulfilled an updated definite diagnosis.

**Diagnostic Performance of the 2 Criteria in Different Conditions**

In consideration of no gold criteria for the PNS, we compared the diagnostic performances of these 2 criteria with given conditions from clinical practice. Generally, the associated antibodies and cancers might be more significant and have specific indicators for the diagnosis of PNS, yet the neurologic phenotypes were also complicated with various mimics. Hence, we divided the cohort into different groups according to the presence of antibodies and cancers for further analyses.

We listed the manifestations of patients in different conditions in Table 3. As expected, compared with patients without antibodies, those with antibodies had concomitant cancers more frequently (p = 0.009). The patients with and without antibodies also had significantly different diagnostic levels by the 2004 and 2021 criteria (p < 0.001). Referring to the PNS-Care Score, the scores of all items showed significance, indicating the great utility of antibodies for diagnosis. Similarly, the type of antibodies was significantly different between patients with and without cancers (p = 0.003). Those with cancers had a higher chance of reaching a definite
diagnosis by the 2 criteria (both p < 0.001). Notably, among those previously definite patients with concomitant antibodies or cancers, nearly half no longer fulfilled the definite diagnosis according to the 2021 criteria.

We then analyzed the diagnostic value of these 2 aspects for the definite PNS diagnosed by the 2 criteria. As shown in Table 4, the sensitivity of the criteria represented as the rate of the definite diagnosis among patients with antibody/cancer was inversely proportional to the omission diagnostic rate. And the specificity represented as the rate of non-definite diagnosis among patients without antibody/cancer suggested the degree of misdiagnosis. Referring to the diagnostic performance of each parameter (antibody and cancer), cancer showed better sensitivity and specificity in both criteria. The presence of cancers might play a more important role in the final diagnosis than antibodies. Yet they performed excellently in the specificity of the 2021 criteria in spite of their general sensitivity.

DISCUSSION

Our study firstly evaluated and compared the diagnostic performance of the 2004 PNS criteria and the 2021 updated revision in a Chinese population. In comparison with the previous criteria, the updated criteria showed a drop of 48.7% in the definite diagnosis rate, with a large proportion (43.4%) turning into probable diagnosis, and 2.7% into the “non-PNS” group. The new PNS-Care Score provided a specific and strict approach to improve the diagnostic accuracy, but its increased risk of underdiagnosis were also needed to be of concern. Above all, the performance of the 2021 criteria could be summarized as follows.

On the one hand, the 2021 criteria increased the accuracy by a strict scoring system in the definite diagnosis. These could be supported by the individual diagnostic performance of the 2 criteria, as a result of an excellent specificity but a lower sensitivity in the 2021 criteria. Referring to the clinical phenotypes, their definitions of terminology were updated and modified according to the latest criteria for a more appropriate summary and classification. For example, the criteria of LE were updated in 2016 (46), yet 12 of 35 patients previously diagnosed with LE no longer met the new criteria and were excluded from the high-risk phenotype.

Moreover, the presence of specific neural antibodies and/or cancer was emphasized in the updated criteria for an unambiguous diagnostic certainty. For instance, among 67 patients diagnosed with definite PNS by the 2004 criteria with well-characterized antibodies and no cancer, there were only 32 (47.8%) meeting the definite level by the 2021 criteria, as the remaining 24 (35.8%) and 11 (16.4%) were probable and possible levels. This might be mainly explained by the larger diagnostic value of cancer itself rather than the antibody in each patient. Meanwhile, among 17 patients with no detectable neural antibodies during follow-up, the diagnosis in 14 patients with a previous definite diagnosis changed into probable (n = 11) and possible (n = 1) diagnoses, as 2 were excluded as non-PNS (each with mucosa-associated lymphoid tissue lymphoma and colorectal carcinoma). Similarly, another patient with inconsistent renal carcinoma was diagnosed with non-PNS. Thus, the presence of associated antibodies and their consistent cancer might be essential for a definite diagnosis. Additionally, the updated criteria could reduce the risk of overdiagnosis and the real burden of PNSs. Nonetheless, we should acknowledge that comprehensive screening for cancers or antibodies was difficult to achieve in all patients, due to their poor economic and physical conditions.
Notably, in the case of inconsistent cancers, the demonstration of antigen expression by the tumor was reasonable and was required for the diagnosis. Hence, special attention should be paid to those patients to avoid overdiagnosis, and additional diagnostic evidence including available clinical features and objective ancillary evidence should be further pursued.

On the other hand, the updated criteria provided a broad spectrum of neural antibodies. For example, the anti-SOX1

### TABLE 3 | Comparison of the diagnostic criteria under specific conditions.

| Overall (n = 113) | Antibody | Cancer |
|------------------|----------|--------|
| Presence (n = 90) | Absence (n = 23) | Presence (n = 81) | Absence (n = 32) |
| Age at onset, years, median (IQR) | 60.0 (53.0–65.0) | 60.0 (54.0–65.8) | 56.0 (50.5–61.5) | 59.0 (53.0–65.0) | 60.0 (62.25–65.0) | 0.781 |
| Male | 69 (61.1) | 51 (56.7) | 18 (78.3) | 0.080 | 50 (61.7) | 19 (59.4) | 0.986 |

**Clinical phenotype**

#### 2004 criteria

| Cancer | Presence (n = 81) | Absence (n = 32) |
|--------|------------------|-----------------|
| Classical | 80 (71.6) | 22 (68.8) | 0.781 |
| Non-classical | 23 (28.4) | 10 (31.2) | 0.986 |

#### 2021 criteria

| Cancer | Presence (n = 81) | Absence (n = 32) |
|--------|------------------|-----------------|
| High-risk | 50 (61.7) | 18 (56.2) | 0.747 |
| Intermediate-risk | 38 (38.3) | 14 (43.8) | 0.986 |

**Antibody**

#### 2004 criteria

| Antibody | Presence (n = 81) | Absence (n = 32) |
|----------|------------------|-----------------|
| Well-characterized | 86 (70.2) | 35 (61.2) | 0.080 |
| Partially characterized | 29 (32.2) | 14 (25.0) | 0.986 |
| Others or negative | 24 (26.7) | 10 (19.0) | 0.781 |

#### 2021 criteria

| Antibody | Presence (n = 81) | Absence (n = 32) |
|----------|------------------|-----------------|
| High-risk | 50 (61.7) | 18 (56.2) | 0.747 |
| Intermediate-risk | 38 (38.3) | 14 (43.8) | 0.986 |

**Cancer**

#### 2004 criteria

| Cancer | Presence (n = 81) | Absence (n = 32) |
|--------|------------------|-----------------|
| Found, consistent with phenotype and (if present) antibody, or not consistent but antigen expression demonstrated | 60 (53.1) | 43 (68.8) | 0.986 |
| Not found/consistent but follow-up < 2 years | 26 (23.0) | 23 (35.3) | 0.986 |
| Not found but follow-up ≥ 2 years | 27 (23.9) | 24 (37.5) | 0.986 |

**Diagnostic level**

#### 2004 criteria

| Level | Presence (n = 81) | Absence (n = 32) |
|-------|------------------|-----------------|
| Definite | 97 (85.8) | 76 (68.6) | 0.080 |
| Possible | 16 (14.2) | 5 (6.2) | 0.986 |

#### 2021 criteria

| Level | Presence (n = 81) | Absence (n = 32) |
|-------|------------------|-----------------|
| Definite | 46 (46.7) | 27 (33.3) | 0.986 |
| Possible | 19 (16.8) | 9 (11.1) | 0.986 |
| Non-PNS | 3 (2.7) | 3 (3.7) | 0.986 |

**PNS-Care Score, median (IQR)**

| Score | Overall (n = 113) |
|-------|------------------|
| Clinical level | 3.0 (2.0–3.0) |
| Laboratory level | 3.0 (2.0–3.0) |
| Cancer | 4.0 (1.0–4.0) |
| Total | 7.0 (6.0–10.0) |

### TABLE 4 | Diagnostic performance of antibody and cancer for a definite diagnosis of PNS by the 2 criteria.

| Sensitivity | Specificity | Positive Predictive Value | Negative Predictive Value | Accuracy |
|-------------|-------------|---------------------------|---------------------------|----------|
| 2004 criteria |
| Antibody | 86.7 (77.9–92.9) | 17.4 (5.0–38.8) | 80.4 (77.0–83.4) | 25.0 (10.6–48.4) | 72.6 (63.4–80.5) |
| Cancer | 93.8 (86.2–96.0) | 34.4 (18.6–53.2) | 78.4 (73.7–82.4) | 68.8 (45.4–85.4) | 77.0 (68.1–84.4) |
| 2021 criteria |
| Antibody | 46.7 (36.1–57.5) | 100.0 (85.2–100.0) | 100.0 (80.0–100.0) | 4.0 (1.0–4.0) | 100.0 (100.0–100.0) |
| Cancer | 51.9 (40.5–63.1) | 100.0 (89.1–100.0) | 100.0 (80.0–100.0) | 45.1 (39.6–50.7) | 65.5 (56.0–74.2) |

All data are stated as percentage with 95% CI confidence interval in the parentheses.

PNS, paraneoplastic neurologic syndrome.
Cai et al. Evaluating the Updated PNS Criteria

The 2021 PNS criteria provided a better clinical application for avoiding overdiagnosis or misdiagnosis than the 2004 criteria. Indeed, the presence of cancer played a more critical and important role in the definite diagnosis. Comprehensive and long-term screening for cancers is essential in suspected PNS. Above all, the updated PNS criteria showed an accurate diagnostic performance by a comprehensive synthesis of clinical phenotypes, antibodies, and cancers. It would provide the clinical utility with the risk stratification to expedite the diagnostic process by prompting recognition and treatment. Nevertheless, in view of the possible delay or underdiagnosis of PNS induced by the updated criteria, timely treatments and close monitoring with long-term follow-up should be performed to improve the prognosis for those with probable/possible diagnoses.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the ethics committee of the Second Affiliated Hospital School of Medicine Zhejiang University. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

M-TC and Y-XZ contributed to the concept and design of the study. All authors contributed to the acquisition and analysis of the data. M-TC and SQ contributed to drafting the initial manuscript. Y-XZ and M-PD contributed to revising the manuscript for intellectual content. All authors read and approved the final version before submission.

FUNDING

This study was supported by the National Natural Science Foundation of China (grant number 82071443).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.790400/full#supplementary-material
Review of the Literature. Mol Clin Oncol (2018) 9(2):163–7. doi: 10.3892/mco.2018.1638

40. Yang J, Du J, Zhao J, Liu H, Zhang L, Cai L, et al. Anti-Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor Encephalitis: A Case Report. Med (Baltimore) (2021) 100(17):e25694. doi: 10.1097/MD.0000000000025694

41. Yuan J, Jia Z, Qin W, Hu W. Paraneoplastic Neuromyelitis Optica Spectrum Disorder Associated With Breast Cancer. Clin Interv Aging (2019) 14:1039–44. doi: 10.2147/CIA.S202102

42. Zhang K, Liu W, Li Y, Zhang K, Gao X, Wang J. Mediastinal Small Cell Cancer Associated With Lambert-Eaton Myasthenic Syndrome: A Case Report. Exp Ther Med (2015) 10(1):117–20. doi: 10.3892/etm.2015.2454

43. Zhang RR, Han T, Guo F, Liu ZZ, Han YL, Chen WC, et al. Lambert-Eaton Myasthenic Syndrome in a Patient With Small-Cell Lung Cancer: A Case Report. Oncol Lett (2015) 10(3):1339–42. doi: 10.3892/ol.2015.3473

44. Zhu L, Deng X, Lai Z, Xie N, Tan W. Paraneoplastic Limbic Encephalitis Cured With Nephron-Sparing Surgery in a Patient With Clear Cell Renal Cell Carcinoma: A Case Report. J Int Med Res (2019) 47(10):5318–22. doi: 10.1177/0300060519863524

45. Zhu Y, Chen S, Chen S, Song J, Chen F, Guo H, et al. An Uncommon Manifestation of Paraneoplastic Cerebellar Degeneration in a Patient With High Grade Urothelial Carcinoma With Squamous Differentiation: A Case Report and Literature Review. BMC Cancer (2016) 16:324. doi: 10.1186/s12885-016-2349-3

46. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A Clinical Approach to Diagnosis of Autoimmune Encephalitis. Lancet Neurol (2016) 15 (4):391–404. doi: 10.1016/S1474-4422(15)00401-9

47. Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A, Lang R, et al. Anti-Glial Nuclear Antibody: Marker of Lung Cancer-Related Paraneoplastic Neurological Syndromes. J Neuroimmunol (2005) 165(1-2):166–71. doi: 10.1016/j.jneuroim.2005.03.020

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Cai, Qiao, Lai, Zheng, Yang, Fang, Shen, Zhang and Ding. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.